Agios begins Phase I/II trial of AG-221 to treat advanced solid tumours

Agios Pharmaceuticals has started a Phase I/II multicentre trial of AG-221 in patients with advanced solid tumours, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news